| Literature DB >> 35116672 |
Yuanhe You1,2,3,4, Zhong Du1,2,3,4, Zhuowei Tian1,2,3,4, Guisong Xu1,2,3,4, Yanan Wang1,2,3,4, Meng Xiao1,2,3,4.
Abstract
BACKGROUND: Immunotherapy strategies are successful in only a subset of patients with advanced head and neck squamous cell carcinoma (HNSCC). The roles of tumor-infiltrating lymphocytes (TILs) in HNSCC are less clear. Herein, we present a preliminary study to identify the underlying heterogeneity and correlations among TILs in HNSCC by bioinformatics analysis of TIL-related biomarkers.Entities:
Keywords: Tumor-infiltrating lymphocytes (TILs); bioinformatics analysis; head and neck squamous cell carcinoma (HNSCC); immunotherapy; programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1)
Year: 2021 PMID: 35116672 PMCID: PMC8798398 DOI: 10.21037/tcr-21-408
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Expression patterns of TIL-related molecules based on the TCGA primary HNSCC cohort. (A) A summary of TIL-related molecules and the encoded genes; (B) schematic diagrams indicating the distribution and relationship between PD-1 and PD-L1; (C) heat-map demonstrating the genetic expression relationships of TIL-related molecules based on the TCGA primary HNSCC cohort; (D) heat-map demonstrating the gene expression relationship between PD-1 and PD-L1 based on the TCGA primary HNSCC cohort; (E) heat-map demonstrating the genetic expression relationships between PD-L1 and each TIL-related molecules based on the TCGA primary HNSCC cohort; (F) heat-map demonstrating the genetic expression relationships between PD-1 and each TIL-related molecules based on the TCGA primary HNSCC cohort. *, significantly positive correlation. TIL, tumor-infiltrating lymphocyte; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; HPV, human papilloma virus.
Clinicopathological evaluation for the TILs related molecules based on the TCGA primary HNSCC cohort
| Clinicopathological features | P value | |||||
|---|---|---|---|---|---|---|
| CD4 | CD8 | CD20 | CD56 | PD-1 | PD-L1 | |
| Pathological stage (I+II/III+IV) | 0.116 | 0.675 | 0.602 | 0.088 | 0.176 | 0.052 |
| Pathological T (T1+T2/T3+T4) | 0.086 | 0.117 | 0.022† | 0.008† | 0.007† | 0.286 |
| Pathological N (N0/N1+) | 0.239 | 0.243 | 0.575 | 0.688 | 0.04‡ | 0.974 |
| Histological Grade (G1+G2/G3+G4) | 0.019‡ | 0.011‡ | 0.967 | 0.499 | 0.04‡ | 0.797 |
| Perineural invasion (yes/no) | 0.598 | 0.946 | 0.001† | 0.006‡ | 0.037† | 0.368 |
| Lymphovascular invasion present (yes/no) | 0.584 | 0.455 | 0.707 | 0.464 | 0.954 | 0.267 |
| Nodal extracapsular spread (yes/no) | 0.457 | 0.248 | 0.03† | 0.799 | 0.639 | 0.720 |
| EGFR amplification status (amplified/unamplified) | 0.096 | 0.238 | 0.679 | 0.701 | 0.182 | 0.701 |
| HPV status by FISH testing (positive/negative) | 0.145 | <0.001‡ | <0.001‡ | 0.002† | <0.001‡ | 0.600 |
| HPV status by p16 testing (positive/negative) | 0.098 | 0.001‡ | 0.003‡ | <0.001† | 0.002‡ | 0.962 |
†, negative correlation; ‡, positive correlation. TILs, tumor-infiltrating lymphocytes; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; HPV, human papilloma virus.
Figure 2Prognosis analyses for PD-L1, PD-1, or TILs related molecules in patients with HNSCC by using Kaplan-Meier Plotter. OS curves of PD-1 (A); CD4 (B); CD8 (C); CD20 (D); and CD56 (E); RFS curves of PD-L1 (F). PD-L1, programmed cell death 1 ligand 1;PD-1, programmed cell death 1; TIL, tumor-infiltrating lymphocyte; HNSCC, head and neck squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
Figure 3Bioinformatics enrichment analysis for the TIL-related markers, PDCD1 and CD274. (A) Co-expression networks for PDCD1, CD274, and TIL-related genes predicted by GeneMANIA; (B) heat-map demonstrating the gene expression relationships between IL2RB and each TIL-related molecule, CD274, or PDCD1 based on the TCGA primary HNSCC cohort; (C) correlation between OS and expression level of IL2RB in patients with HNSCC by using Kaplan-Meier Plotter. *, significantly positive correlation; TIL, tumor-infiltrating lymphocyte; HNSCC, head and neck squamous cell carcinoma; OS, overall survival.
Clinicopathological evaluation for IL2RB based on the TCGA primary HNSCC cohort
| Variable | N | IL2RB expression (≤8.5) | IL2RB expression (>8.5) | P value |
|---|---|---|---|---|
| Pathologic T | 0.006† | |||
| T1+T2 | 184 | 80 | 104 | |
| T3+T4 | 273 | 155 | 118 | |
| Pathologic N | 0.692 | |||
| N0 | 176 | 95 | 81 | |
| N1+ | 244 | 126 | 118 | |
| Pathologic stage | 0.013† | |||
| I+II | 101 | 41 | 60 | |
| III+IV | 347 | 191 | 156 | |
| Neoplasm histologic grade | 0.068 | |||
| G1+G2 | 366 | 193 | 173 | |
| G3+G4 | 132 | 57 | 75 | |
| Lymphovascular invasion present | 0.574 | |||
| Yes | 123 | 69 | 54 | |
| No | 225 | 118 | 107 | |
| Pathological nodal extracapsular spread | 0.068 | |||
| Yes | 112 | 67 | 45 | |
| N0 | 244 | 120 | 124 | |
| Perineural invasion present | 0.246 | |||
| Yes | 169 | 96 | 73 | |
| N0 | 193 | 97 | 96 | |
| EGFR amplication | 0.061 | |||
| Amplified | 11 | 7 | 4 | |
| Unamplified | 16 | 4 | 12 | |
| HPV status by FISH | 0.009† | |||
| Positive | 21 | 3 | 18 | |
| Negative | 65 | 31 | 34 | |
| HPV status by p16 testing | 0.025† | |||
| Positive | 38 | 10 | 28 | |
| Negative | 73 | 36 | 37 |
†, negative correlation. HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus.